Previous 10 | Next 10 |
2023-11-03 10:42:01 ET Organon & Co ( NYSE: OGN ) has been downgraded by Goldman Sachs from Buy to Neutral after the Merck spinoff fell short of both top and bottom line expectations in its latest Q3 report . Revenue in women's health, Organon's biggest unit, fell 8% Y/Y...
2023-11-03 00:55:40 ET Summary SPDR S&P 600 Small Cap Value ETF is invested in over 400 small caps with a tilt to value over growth. It is well-diversified across sectors and holdings. The sector breakdown, valuation ratios and historical performance are not much different...
2023-11-02 13:29:17 ET Shares of Organon ( NYSE: OGN ) on Thursday slumped as much as 12.5% to a record low of $12.83, after the company saw a quarterly revenue decline in its main women's health business. Pharmaceutical giant Merck ( MRK ) spun-off Organon ( OGN ) i...
2023-11-02 12:21:05 ET Organon & Co (OGN) Q3 2023 Earnings Conference Call November 2, 2023 8:30 AM ET Company Participants Jennifer Halchak - VP, IR Kevin Ali - CEO Matthew Walsh - CFO Sandra Milligan - Head of R&D Conference Call Participants ...
2023-11-02 09:00:00 ET Summary Pfizer's stock has dropped due to a decline in revenues post-COVID, presenting a value investment opportunity. The company still generates significant gross profit and has a strong revenue growth rate. Pfizer's low Price-to-Earnings ratio and imp...
2023-11-02 07:31:27 ET More on Organon Organon: The Federal Reserve Black Swan (Rating Upgrade) 6% Yield And Significantly Undervalued: A Closer Look At Organon Organon Q2 2023 Earnings Review: Incremental Growth With A Slather Of Risk Organon Q3 2023 Earning...
Third quarter 2023 revenue of $1,519 million Third quarter 2023 diluted earnings per share of $0.23 and non-GAAP Adjusted diluted earnings per share of $0.87 Adjusted EBITDA of $447 million Board of Directors declares quarterly dividend of $0.28 per share Full year 2023 financial ...
Acushnet Holdings Corp. (GOLF) is expected to report $0.54 for Q3 2023 Paramount Global (PARA) is expected to report $0.09 for Q3 2023 Curis Inc. (CRIS) is expected to report $-2.32 for Q3 2023 Quanta Services Inc. (PWR) is expected to report $1.99 for Q3 2023 GRI Bio Inc. (GRI) i...
Organon & Co. (OGN) is expected to report $1.04 for Q3 2023
2023-11-01 12:56:56 ET More on Organon Organon: The Federal Reserve Black Swan (Rating Upgrade) 6% Yield And Significantly Undervalued: A Closer Look At Organon Organon Q2 2023 Earnings Review: Incremental Growth With A Slather Of Risk Hennessy Funds is bulli...
News, Short Squeeze, Breakout and More Instantly...
VANCOUVER, BC / ACCESSWIRE / July 31, 2024 / (TSXV:OGN)(OTCQX:OGNRF) Orogen Royalties Inc. ("Orogen" or the "Company") is pleased to announce a new significant gold-silver discovery, called the Navidad vein system, on the Ermitaño Mine concessions in Sonora, Mexico where the Company holds a...
VANCOUVER, BC / ACCESSWIRE / July 24, 2024 / (TSXV:OGN)(OTCQX:OGNRF) Orogen Royalties Inc. ("Orogen" or the "Company") is pleased to announce updates for its partner funded exploration stage projects and royalties. Highlights Estimated 30,000 metres of drilling in seven planned or comp...
Company estimates $15 million of milestone expense in the second quarter Organon (NYSE: OGN), a global healthcare company with a focus on women’s health, will release its second quarter 2024 financial results on August 6, 2024, prior to the company’s webcast and conference...